Rating of CCl4-induced rat liver fibrosis by blood serum glycomics

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 7, 2007, Pages 1148-1154

  Desmyter, Liesbeth ^a   Fan, Ye Dong ^b   Praet, Marleen ^b   Jaworski, Tomasz ^a   Vervecken, Wouter ^a   De Hemptinne, Bernard ^b   Contreras, Roland ^a   Chen, Cuiying ^a  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Fibrosis; Glycosylation; GlycoTest; Liver cirrhosis; N glycan; Non invasive; Serum biomarker

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARBOHYDRATE; CARBON TETRACHLORIDE; DNA; GAMMA INTERFERON; GLYCAN DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CARBOHYDRATE ANALYSIS; CHEMICAL ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; ENZYME ACTIVITY; GLYCOBIOLOGY; LIVER CIRRHOSIS; LIVER FIBROSIS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SCORING SYSTEM; SERUM; STATISTICAL SIGNIFICANCE; TREATMENT DURATION;

EID: 34347370096     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04553.x     Document Type: Article

References (35)

1. Desmet VJ, Roskams T. Cirrhosis reversal: a duel between dogma and myth. J. Hepatol. 2004 40 : 860 7.
2. Friedman SL. Liver fibrosis: from bench to bedside. J. Hepatol. 2003 38 (Suppl. 1 S38 53.
3. Ozer E, Helvaci M, Yaprak I. Hepatic expression of viral antigens, hepatocytic proliferative activity and histologic changes in liver biopsies of children with chronic hepatitis B after interferon-alpha therapy. Liver 1999 19 : 369 74.
4. Poynard T, McHutchison J, Davis GL et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000 32 : 1131 7.
5. Schuppan D, Jia JD, Brinkhaus B, Hahn EG. Herbal products for liver diseases: a therapeutic challenge for the new millennium. Hepatology 1999 30 : 1099 104.
6. Selden C, Hodgson H. Cellular therapies for liver replacement. Transpl. Immunol. 2004 12 : 273 88.
7. Olthoff KM. Molecular pathways of regeneration and repair after liver transplantation. World J. Surg. 2002 26 : 831 7.
8. Pinzani M, Rombouts K. Liver fibrosis: from the bench to clinical targets. Dig. Liver Dis. 2004 36 : 231 42.
9. Rosenberg WM. Rating fibrosis progression in chronic liver diseases. J. Hepatol. 2003 38 : 357 60.
10. Afdhal NH. Biopsy or biomarkers: is there a gold standard for diagnosis of liver fibrosis? Clin. Chem. 2004 50 : 1299 300.
11. Zeremski M, Talal AH. Noninvasive markers of hepatic fibrosis: are they ready for prime time in the management of HIV/HCV co-infected patients? J. Hepatol. 2005 43 : 2 5.
12. Oberti F, Valsesia E, Pilette C et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 1997 113 : 1609 16.
13. Myers RP, Tainturier MH, Ratziu V et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J. Hepatol. 2003 39 : 222 30.
14. Le Calvez S, Thabut D, Messous D et al. The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C. Hepatology 2004 39 : 862 3.
15. Lebensztejn DM, Skiba E, Sobaniec-Lotowska M, Kaczmarski M. A simple noninvasive index (APRI) predicts advanced liver fibrosis in children with chronic hepatitis B. Hepatology 2005 41 : 1434 5.
16. Kelleher TB, Mehta SH, Bhaskar R et al. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J. Hepatol. 2005 43 : 78 84.
17. Iacobellis A, Mangia A, Leandro G et al. External validation of biochemical indices for noninvasive evaluation of liver fibrosis in HCV chronic hepatitis. Am. J. Gastroenterol. 2005 100 : 868 73.
18. Castera L, Vergniol J, Foucher J et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005 128 : 343 50.
19. Poynard T, Imbert-Bismut F, Munteanu M, Ratziu V. FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis? Expert Rev. Mol. Diagn. 2005 5 : 15 21.
20. Imbert-Bismut F, Messous D, Thibault V et al. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. Clin. Chem. Lab. Med. 2004 42 : 323 33.
21. Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat. Med. 2004 10 : 429 34.
22. Jaeken J, Carchon H. Congenital disorders of glycosylation: a booming chapter of pediatrics. Curr. Opin. Pediatr. 2004 16 : 434 9.
23. Dube DH, Bertozzi CR. Glycans in cancer and inflammation: potential for therapeutics and diagnostics. Nat. Rev. Drug Discov. 2005 4 : 477 88.
24. Freeze HH, Westphal V. Balancing N-linked glycosylation to avoid disease. Biochimie 2001 83 : 791 9.
25. Axford JS. Glycosylation and rheumatic disease. Biochim. Biophys. Acta 1999 1455 : 219 29.
26. Peracaula R, Tabares G, Royle L et al. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins. Glycobiology 2003 13 : 457 70.
27. Callewaert N, Schollen E, Vanhecke A, Jaeken J, Matthijs G, Contreras R. Increased fucosylation and reduced branching of serum glycoprotein N-glycans in all known subtypes of congenital disorder of glycosylation I. Glycobiology 2003 13 : 367 75.
28. Takahara T, Sugiyama K, Zhang LP et al. Cotreatment with interferon-alpha and -gamma reduces liver fibrosis in a rat model. Hepatol. Res. 2004 28 : 146 54.
29. Callewaert N, Geysens S, Molemans F, Contreras R. Ultrasensitive profiling and sequencing of N-linked oligosaccharides using standard DNA-sequencing equipment. Glycobiology 2001 11 : 275 81.
30. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994 20 : 15 20.
31. Baroni GS, D'Ambrosio L, Curto P et al. Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis. Hepatology 1996 23 : 1189 99.
32. Sakaida I, Uchida K, Matsumura Y, Okita K. Interferon gamma treatment prevents procollagen gene expression without affecting transforming growth factor-beta1 expression in pig serum-induced rat liver fibrosis in vivo. J. Hepatol. 1998 28 : 471 9.
33. Dwek RA. Biological importance of glycosylation. Dev. Biol. Stand. 1998 96 : 43 7.
34. Trombetta ES, Parodi AJ. Glycoprotein reglucosylation. Methods 2005 35 : 328 37.
35. Galili U, Shohet SB, Kobrin E, Stults CL, Macher BA. Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells. J. Biol. Chem. 1988 263 : 17 55 62.